xifu liu

Prof. Dr. xifu liu


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MWMo Wang
Mo Wang
JLJiawei Liu
Jiawei Liu
MXMingjing Xia
Mingjing Xia
LYLibinghan Yin
Libinghan Yin
LZLing Zhang
Ling Zhang
CYCheng Yu
Cheng Yu

28 February 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
LGLichao Guo
Lichao Guo
WZWen Zhang
Wen Zhang
YXYanqi Xie
Yanqi Xie
XCXi Chen
Xi Chen
EOEmma E. Olmstead
Emma E. Olmstead
CLChunming Liu
Chunming Liu
Cancer cells undergo significant “metabolic remodeling” to provide sufficient ATP to maintain cell survival and to promote rapid growth. In colorectal cancer cells, ATP is produced by mitochondrial oxidative phosphorylation and by substantially elevated cytoplasmic glucose fermentation (i.e., the Warburg effect). Glucose transporter 1 (GLUT1) expression is significantly increased in colorectal cancer cells, and GLUT1 inhibitors block glucose uptake and hence glycolysis crucial for cancer cell growth. In addition to ATP, these metabolic pathways also provide macromolecule building blocks and signaling molecules required for tumor growth. In this study, we identify a diaminobutoxy-substituted isoflavonoid (DBI-1) that inhibits mitochondrial complex I and deprives rapidly growing cancer cells of energy needed for growth. DBI-1 and the GLUT1 inhibitor, BAY-876, synergistically inhibit colorectal cancer cell growth in vitro and in vivo. This study suggests that an electron transport chain inhibitor (i.e., DBI-1) and a glucose transport inhibitor, (i.e., BAY-876) are potentially effective combination for colorectal cancer treatment.

24 September 2020 in Food & Function
Verified
Journal Article
Closed access
PDF file
MDMeijun Dong
Meijun Dong
LLLisi Li
Lisi Li
GLGuowei Li
Guowei Li
JSJunna Song
Junna Song
BLBaolin Liu
Baolin Liu
MWMeng Wang
Meng Wang
Adipose dysfunction is closely associated with alcoholic liver disease. The impact of mangiferin on ethanol-induced liver injury and the probable underlying molecular mechanism has not been sufficiently addressed. In the present study, mice were subjected to a chronic plus a single binge ethanol feeding to induce liver injury. In addition, the differentiated adipocytes from primary mouse adipocytes were isolated and used for the mechanism studies. Our study demonstrated that mangiferin protects against ethanol induced adipose hyperlipolysis by restoring PDE3B stability, which is associated with activating the AMPK/TBK1 signaling and suppressing the noncanonical NF-κB activation, leading to the reduction of free fatty acid release and the amelioration of ethanol-induced liver injury. Our findings identify that mangiferin ameliorates alcoholic liver injury via suppression of inflammation-induced adipose hyperlipolysis, suggesting that mangiferin might be a potential effective agent for the management of alcoholic liver injury.

5 July 2023 in Microbes and Infection
Verified
Journal Article
Closed access
YLYanning Li
Yanning Li
HSHongbo Si
Hongbo Si
YMYujie Ma
Yujie Ma
SLShuang Li
Shuang Li
LGLijie Gao
Lijie Gao
XLxifu liu
xifu liu

1 December 2023 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
NMNi Meng
Ni Meng
XCXiaolong Cheng
Xiaolong Cheng
MSMengyao Sun
Mengyao Sun
YZYushan Zhang
Yushan Zhang
XSXueke Sun
Xueke Sun
JCJing Chen
Jing Chen
Introduction: The monkeypox (Mpox) virus epidemic presents a significant risk to global public health security. A35R, a crucial constituent of EEV, plays a pivotal role in virus transmission, serves as a vital target for vaccine development, and has potential for serological detection. Currently, there is a dearth of research on nanobodies targeting A35R. The purpose of this study is to identify specific nanobodies target A35R, so as to provide new antibody candidates for Mpox vaccine development and diagnostic kit development. Methods: Three nanobodies specific to the monkeypox virus protein A35R were screened from a naïve phage display library. After four rounds of panning, positive phage clones were identified by enzyme-linked immunosorbent assay (ELISA). Further, the nanobody fusion protein was constructed in pNFCG1-IgG1-Fc vector and expressed in HEK293F cells and purified by affinity chromatography. The specificity and affinity of the nanobodies were identified by ELISA. The binding kinetics of the VHH antibody to A35R were assessed via employment of a bio-layer interferometry (BLI) apparatus, thereby determining the nanobodies affinity. Results: The three purified nanobodies showed specific high-affinity binding MPXV A35R, of them, VHH-1 had the best antigen binding affinity (EC50 = 0.010 ug/mL). In addition, VHH-1 on Protein A biosensor can bind Mpox virus A35R, with an affinity constant of 54 nM as determined in BLI assay. Conclusion: In sum, we has obtained three nanobody strains against Mpox virus A35R with significant affinity and specificity, therefore laying an essential foundation for further research as well as the applications of diagnostic and therapeutic tools of Mpox virus.

12 March 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SLShuang Li
Shuang Li
JZJiayi Zhang
Jiayi Zhang
XLXinxing Liu
Xinxing Liu
NWNingmei Wang
Ningmei Wang
LSLuyao Sun
Luyao Sun
XLxifu liu
xifu liu
In recent years, human umbilical cord mesenchymal stem cell (hUC-MSC) extracellular vesicles (EVs) have been used as a cell replacement therapy and have been shown to effectively overcome some of the disadvantages of cell therapy. However, the specific mechanism of action of EVs is still unclear, and there is no appropriate system for characterizing the differences in the molecular active substances of EVs produced by cells in different physiological states. We used a data-independent acquisition (DIA) quantitative proteomics method to identify and quantify the protein composition of two generations EVs from three different donors and analysed the function and possible mechanism of action of the proteins in EVs of hUC-MSCs via bioinformatics. By comparative proteomic analysis, we characterized the different passages EVs. Furthermore, we found that adaptor-related protein complex 2 subunit alpha 1 (AP2A1) and adaptor-related protein complex 2 subunit beta 1 (AP2B1) in hUC-MSC-derived EVs may play a significant role in the treatment of Alzheimer's disease (AD) by regulating the synaptic vesicle cycle signalling pathway. Our work provides a direction for batch-to-batch quality control of hUC-MSC-derived EVs and their application in AD treatment.